Facet browsing currently unavailable
Page 1 of 1 results
Sort by: relevance publication year
Showing DOI matching
10.1016/S0140-6736(14)60958-2
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial JOURNAL ARTICLE published September 2014 in The Lancet |